| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Patients with isolation of carbapenem-resistant Enterobacteriaceae (CRE) with meropenem were included from 08/2016 to 03/2018. Ninety isolates (27 CPE and 63 NCPE) were collected from 88 patients (53 male) in 9 hospitals. CPE (Carbapenemase-producing Enterobacteriaceae)included 10 E. cloacae (ENC), 6 K. pneumoniae (KP), 4 E. coli (EC), 3 C. freundii (CF), 2 K. oxytoca, and 1 each of E. aerogenes (EA) and S. marcescens (SM). NCPE (Non-CPE) included 34 EA, 15 ENC, 4 each of EC, KP, SM, and 2 CF. All CPE were positive for IMP carbapenemase. Levofloxacin, gentamicin, and amikacin resistance were found in 6 (22%), 4 (15%), and 1 (4%) CPE, respectively, and 6 (10%), 6 (10%), and 0 NCPE, respectively. Cases of CPE involved older patients with more frequent use of devices and carbapenem exposure. The mortality was similar in the 2 groups. Length of hospital stay after CPE/NCPE isolation was higher in the CPE group after adjustment for the confounding effects.
|
